Three promising studies featuring psilocybin, LSD and MDMA have shown signs of improved brain function.
Awakn Life Sciences and the University of Exeter (UoE) are collaborating to put in place a framework for a Phase 3 trial exploring the use of...
Patients with Major Depressive disorder (MDD) have been shown to achieve remission within three months following treatment with SPL026 combined with supportive therapy in Small Pharma’s...
Study participants demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the...
Beckley Psytech has initiated a Phase IIa study of its 5-MeO-DMT candidate – BPL-003 – for Alcohol Use Disorder (AUD), which will take place at King’s...
While psychedelic research has, to date, largely focused on mathematical modelling and resting-state neuroimaging, cognitive neuroscientists are bringing new rigour to the field through the use...
Researchers from the Universidade de São Paulo (USP) and ICEERS have found that ayahuasca may modulate neural networks, and suggest that more research is needed to...
Psyched Wellness has carried out a neurobehavioral study evaluating the safety and efficacy of its Amanita Muscaria extract – AME-1.
Mind Medicine Australia has provided funding for two studies that will be investigating the use of psilocybin and MDMA.
Detailed brain imaging data from 20 healthy volunteers has revealed how DMT increased connectivity across the brain, with more communication between different areas and systems.